THE RESULTS OF SURGICAL TREATMENT OF PATIENTS WITH ADRENAL TUMORS

Malignant adrenal tumors such as adrenocortical cancer (ACC) and malignant pheochromocytoma (MPCC) have a particularly aggressive course, leading to higher mortality in these patients, especially in the later stages of the disease. In this regard, there is a statistically significant difference in survival of patients, depending on the time of detection and initiation of treatment.

Purpose. Analysis of the results of surgical treatment of patients with adrenal tumors.

Patients and methods. 55 patients aged from 17 to 75 years (median 50 ± 13 years) with primary tumor neoplasms of the adrenal gland underwent surgical treatment in the period from 1999 to 2014 in the Department of Onco-urology, P. Hertsen MORI. 18 adrenalectomy (32,7%) completed laparoscopy, 36 (65,5%) – open access, 1 (1,8%) – videoassistance. Among them, retroperitoneal lymph node dissection with ipsilateral hand made in 14 (25.5%), combined operations with resection of adjacent organs – 7 (12,7%), thrombectomy with resection of the inferior Vena cava – 3 (5,5%) cases. The median time was 100 ± 73 minutes in open surgical procedures – 183 ± 55 minutes, laparoscopic – 60 ± 30 minutes. The volume of blood loss – 300 ± 1136 ml. According to the routine morphological studies, 24 (43,6%) patients the tumor were benign, the remaining 31 (56,4%) – malignant.

Results. Long-term results have been traced in 84% of patients in group with ACC. The observation time for patients varied from 2 to 167 months, with a median of 64.5 (IQR 22–111) months. Median survival without progression and 5-year overall and tumor survival was: I stage – 93 months and 67 ± 13%, II stage – 30 months and 75 ± 21%, III stage– 18 months and 67 ± 27%, IV stage – 10 months and 25 ± 21%. The observation time for patients with MPCC varies from 12 to 102 months, with a median of 60 (IQR 18–102) months. Median survival without progression was 26 (IQR 15 to 38) months, 5-year overall and tumor survival was 33 ± 27%.

1. Young WF Jr. Clinical practice. The incidentally discovered adrenal mass. New Engl J Med. 2007; 356 (6): 601–610. DOI: http://dx.doi.org/10.1056/nejmcp065470

2. Kassi E., Kaltsas G., Zografos G. N., Chrousos G. Current issues in the diagnosis and management of adrenocortical carcinomas. Expert Rev Endocrinol Metab. 2010; 5: 451–466. https://www.ncbi.nlm.nih.gov/books/NBK279009/

3. Barzon L., Sonino N., Fallo F., Palu G., Boscaro M. Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol. 2003; 149 (4): 273–285. DOI: http://www.eje-online.org/content/149/4/273.long

4. Kloos R. T., Gross M. D., Francis I. R., Korobkin M., Shapiro B. Incidentally discovered adrenal masses. Endocr Rev. 1995; 16 (4): 460–484. DOI: http://dx.doi.org/10.1210/edrv-16–4-460

5. Mansmann G., Lau J., Balk E., Rothberg M., Miyachi Y., Bornstein S. R. The clinically inapparent adrenal mass: update in diagnosis and management. Endocr Rev. 2004; 25 (2): 309–340. DOI: http://dx.doi.org/10.1210/er.2002–0031

6. Fassnacht M., Libé R., Kroiss M., Allolio B. Adrenocortical carcinoma: a clinician’s update. Nat Rev Endocrinol. 2011; 7 (6): 323–335. DOI: http://dx.doi.org/10.1038/nrendo.2010.235

7. Pacak K., Eisenhofer G., Ahlman H., Bornstein S. R., Gimenez-Roqueplo A. P., Grossman A. B., et al. International symposium on pheochromocytoma. Pheochromocytoma: recommendations for clinical practice from the first international symposium. October 2005. Nat Clin Pract Endocrinol Metab. 2007; 3 (2): 92–102. DOI: http://dx.doi.org/10.1038/ncpendmet0396

8. Zlokachestvennye novoobrazovaniya v Rossii v 2014 g [Malignant neoplasms in Russia in 2014]. Ed by Kaprin A. D., Starinskii V. V., Petrova G. V. Мoscow: P. Hertsen Moscow Oncology Research Institute – Branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, 2016. Available at: http://www.oncology.ru/service/statistics/malignant_tumors/2014.pdf. Accessed 17.08.2016. (In Russian).

9. Icard P., Chapuis Y., Andreassian B., Bernard A., Proye C. Adrenocortical carcinoma in surgically treated patients: a retrospective study on 156 cases by the French Association of Endocrine Surgeons. Surgery. 1992; 112 (6): 972–979.

10. Berruti A., Baudin E., Gelderblom H., Haak H. R., Porpiglia F., Fassnacht M., Pentheroudakis G; ESMO Guidelines Working Group. Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012 Oct; 23 Suppl 7: vii131–8. DOI: http://dx.doi.org/10.1093/annonc/mds231

11. Dedov I. I., Mel’nichenko G. A., Fadeev V. V. Endokrinologiya [Endocrinology]. Moscow: “Litterra” Publ., 2015, 412 p. (In Russian).

12. Markou A, Tsigou K, Papadogias D, Kossyvakis K, Vamvakidis K, Kounadi T., et al. A unique case of a benign adrenocortical tumor with triple secretion of cortisol, androgens, and aldosterone: development of multiple sclerosis after surgical removal of the tumor. Hormones (Athens). 2005; 4 (4): 226–230. http://www.hormones.gr/99/article/article.html

13. Lughezzani G., Sun M., Perrotte P., Jeldres C., Alasker A., Isbarn H., et al. The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation. Eur J Cancer. 2010 Mar; 46 (4): 713–719. DOI: http://dx.doi.org/10.1016/j.ejca.2009.12.007

14. Allolio B., Fassnacht M. Clinical review: Adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab. 2006; 91 (6): 2027–2037. DOI: http://dx.doi.org/10.1210/jc.2005–2639

15. Kuznetsov N. S., Beltsevich D. G., Goncharov N. P., Kats L. Ye., Katsla G. V., Kolesnikova G. S. et al. Elevated level of methylated catecholamine derivatives is a pathognomic laboratory sign of pheochromocytoma. Problemi Endocrinologii (Problems of Endocrinology). 2007; 53 (1): 33–36. (In Russian).

16. Melnichenko G. A., Stilidi I. S., Alekseev B.Ya., Gorbunova V. A., Beltsevich D. G., Raikhman A. O., et al. Federal clinical practice guidelines on the diagnostics and treatment of adrenocortical cancer. Problemi Endocrinologii (Problems of Endocrinology). 2014; 60 (2): 51–67. (In Russian).

17. Kimura N., Watanabe T., Noshiro T., Shizawa S., Miura Y. Histological grading of adrenal and extra-adrenal pheochromocytomas and relationship to prognosis: a clinicopathological analysis of 116 adrenal pheochromocytomas and 30 extra-adrenal sympathetic paragangliomas including 38 malignant tumors. Endocr Pathol. 2005; 16 (1): 23–32.

18. Weiss L. M. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol. 1984; 8 (3): 163–169.

19. van Slooten H., Schaberg A., Smeenk D., Moolenaar A. J. Morphologic characteristics of benign and malignant adrenocortical tumors. Cancer. 1985; 55 (4): 766–773. DOI: http://dx.doi.org/10.1002/1097–0142 (19850215)55:4<766:: aid-cncr2820550414>3.0.co;2–7

20. Aubert S., Wacrenier A., Leroy X., Devos P., Carnaille B., Proye C., et al. Weiss system revisited: a clinicopathologic and immunohistochemical study of 49 adrenocortical tumors. Am J Surg Pathol. 2002; 26 (12): 1612–1619.

21. van’t Sant H. P., Bouvy N. D., Kazemier G., Bonjer H. J., Hop W. C., Feelders R. A., et al. The prognostic value of two different histopathological scoring systems for adrenocortical carcinomas. Histopathology. 2007; 51 (2): 239–245. DOI: http://dx.doi.org/10.1111/j.1365–2559.2007.02747.x